Skip to main content
. 2020 Nov 26;11(4):1119–1138. doi: 10.1016/j.jcmgh.2020.11.007

Figure 2.

Figure 2

BM MB-HSCs were activated and depleted in DSS-induced acute colitis. (A) FACS plots showed the percentage of HSPCs (Lin−c-kit+Sca-1+, LSK), HSCs, and GFP+ HSCs among up-level populations from different time points of 5% DSS treatment. Comparison of the percentage of GFP+ HSCs among (B) lineage-negative cells and (C) HSCs from different time points of 5% DSS treatment. (D) Number of BM GFP+ HSCs from different time points of 5% DSS treatment. (E) Correlation analysis between the number of BM GFP+ HSCs and the histologic score of DSS-induced colitis. (F) Percentage of GFP+MPP3 among lineage-negative cells from different time points of 5% DSS treatment. Comparison of the percentage of GFP+ HSCs among (G) lineage-negative cells and (H) HSCs, and (I) the number of GFP+ HSCs from spleen at different time points of 5% DSS treatment. (J) Percentage of GFP+MPP3 among lineage-negative cells from spleen at different time points of 5% DSS treatment. Cell-cycle analysis with FACS for (K) Ki67 and Hoechst 33342 staining and (L) the percentage of G0 cells of BM HSCs and HSPCs at 5 days after 5% DSS treatment compared with the control group. (M) Percentage of BrdU+ cells of BM GFP+ HSCs from different time points of 5% DSS treatment. Data are expressed as means ± SEM. Results are representative of at least 3 independent experiments. ∗P < .05, ∗∗P < .01.